In a nutshell This scientific article tried to prove that acquired resistance to the chemotherapeutic agent Docetaxel (Taxotere) can be eliminated by specifically targeting the mechanisms of resistance with additional drugs. The main finding was that a new cocktail of chemotherapeutic drugs can inhibit resistance to Docetaxel in studies performed on...
Read MoreCurrent treatment status-Undergoing active treatment-No response Posts on Medivizor
Non-cancerous cells in the prostate contribute to the aquired tumor resistance to chemotherapy
Regretfully, metastatic forms of prostate cancer (spread to distant sites via the blood system) treated with chemotherapy often acquire resistance to the drug, partially due to the repetitive nature of treatment. Resistance leads to tumor progression and treatment failure. This scientific article proposes a novel therapeutic target named WNT16B that...
Read MoreCombined safety results of 4 clinical trials using sipuleucel-T in patients with prostate cancer
In a nutshell The present study summarized the outcomes of four clinical trials assessing the side-effects reported with sipuleucel-T treatment in patients with prostate cancer. The combined results indicated that this drug is relatively safe with mostly mild to moderate, short-term, and reversible side-effects. Some background As of...
Read MoreThe use of systemic chemotherapy for patients with poorly differentiated and signet cell adenocarcinoma of the appendix
In a nutshell The present study evaluated the effects of systemic chemotherapy and cytoreductive surgery (CRS) on survival in patients with aggressive types of cancer of the appendix (poorly differentiated and signet ring cell adenocarcinoma). The main findings were that systemic chemotherapy appears to be a viable treatment option for these types of...
Read MoreNew drugs for advanced prostate cancer
The aim of this article was to describe some of the most interesting developments concerning new therapies for advanced prostate cancer. During the last years new experimental therapeutic agents for the treatment of advanced prostate cancer have been developed. These are based on the recent discoveries on prostate cell function, resistance to...
Read MoreExperimental drug – Enzalutamide – moderately increases survival in patients with advanced prostate cancer
In a nutshell This clinical trial evaluated the survival benefits of a drug named Enzalutamide (Xtandi) for patients with non-responsive (refractory) advanced prostate cancer previously treated with chemotherapy. Main findings: Enzalutamide prolonged survival by approximately 5 months and reduced the risk of death by 37%. Some background The...
Read More
